Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H19ClN2 |
Molecular Weight | 310.821 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
ClC1=CC2=C(C=C1)C(=C3CCNCC3)C4=C(CC2)C=CC=N4
InChI
InChIKey=JAUOIFJMECXRGI-UHFFFAOYSA-N
InChI=1S/C19H19ClN2/c20-16-5-6-17-15(12-16)4-3-14-2-1-9-22-19(14)18(17)13-7-10-21-11-8-13/h1-2,5-6,9,12,21H,3-4,7-8,10-11H2
Molecular Formula | C19H19ClN2 |
Molecular Weight | 310.821 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/11243504Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11243504
Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021165s017,021300s014,021312s015,021563s003lbl.pdf
Desloratadine is an active, descarboethoxy metabolite of loratadine. It acts by selective inhibition of H1 histamine receptor and thus provides relief to patients with allergic rhinitis and chronic idiopathic urticaria. Desloratadine was approved by FDA and it is currently marketed under the name Clarinex (among the others).
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL231 |
0.87 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | CLARINEX Approved UseDesloratadine Tablets are indicated for: Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Chronic Idiopathic Urticaria. Launch Date1.00889277E12 |
|||
Palliative | CLARINEX Approved UseDesloratadine Tablets are indicated for: Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Chronic Idiopathic Urticaria. Launch Date1.00889277E12 |
|||
Palliative | CLARINEX Approved UseDesloratadine Tablets are indicated for: Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Chronic Idiopathic Urticaria. Launch Date1.00889277E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4 ng/mL |
5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DESLORATADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
56.9 ng × h/mL |
5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DESLORATADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
27 h |
5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DESLORATADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
84.5% |
5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DESLORATADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
1.25 mg 1 times / day steady, oral Dose: 1.25 mg, 1 times / day Route: oral Route: steady Dose: 1.25 mg, 1 times / day Sources: Page: p. 25 |
unhealthy, 2-11 years n = 48 Health Status: unhealthy Age Group: 2-11 years Sex: M+F Population Size: 48 Sources: Page: p. 25 |
Disc. AE: Somnolence, Abdominal pain... AEs leading to discontinuation/dose reduction: Somnolence (1 patient) Sources: Page: p. 25Abdominal pain (1 patient) |
45 mg 1 times / day multiple, oral Highest studied dose Dose: 45 mg, 1 times / day Route: oral Route: multiple Dose: 45 mg, 1 times / day Sources: |
healthy, adult Health Status: healthy Age Group: adult Sex: M+F Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Abdominal pain | 1 patient Disc. AE |
1.25 mg 1 times / day steady, oral Dose: 1.25 mg, 1 times / day Route: oral Route: steady Dose: 1.25 mg, 1 times / day Sources: Page: p. 25 |
unhealthy, 2-11 years n = 48 Health Status: unhealthy Age Group: 2-11 years Sex: M+F Population Size: 48 Sources: Page: p. 25 |
Somnolence | 1 patient Disc. AE |
1.25 mg 1 times / day steady, oral Dose: 1.25 mg, 1 times / day Route: oral Route: steady Dose: 1.25 mg, 1 times / day Sources: Page: p. 25 |
unhealthy, 2-11 years n = 48 Health Status: unhealthy Age Group: 2-11 years Sex: M+F Population Size: 48 Sources: Page: p. 25 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
likely | ||||
likely | ||||
likely | ||||
likely | no (pharmacogenomic study) Comment: pharmacogenotype 2C19 does not correlate with systemic exposure Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=19 Page: 19.0 |
|||
likely | no (pharmacogenomic study) Comment: lack of correlation in between 2D6 genotype and 3-OH DCL formation Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-165_Clarinex_biopharmr_P1.pdf#page=10 Page: 10.0 |
|||
likely | weak (co-administration study) Comment: Coadministration of ketonconazole, mean drug Cmax and AUC0-24 values at steady state were increased by 29-45% and 21-39%, respectively; Coadministration with erythromycin, mean drug Cmax and AUC 0-24 at steady state were increased by 24% and 14%, respectively. Page: 10.0 |
|||
Sources: https://dmd.aspetjournals.org/content/43/9/1294 Page: 1.0 |
yes | |||
yes | weak (co-administration study) Comment: Coadministration of ketonconazole, mean drug Cmax and AUC0-24 values at steady state were increased by 29-45% and 21-39%, respectively; Coadministration with erythromycin, mean drug Cmax and AUC 0-24 at steady state were increased by 24% and 14%, respectively. |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Advances in allergy management. | 2002 |
|
Impact and modulation of nasal obstruction. | 2002 |
|
Chronic urticaria: impact of allergic inflammation. | 2002 |
|
Therapeutic points of intervention and clinical implications: role of desloratadine. | 2002 |
|
Investigation of an enhanced resolution triple quadrupole mass spectrometer for high-throughput liquid chromatography/tandem mass spectrometry assays. | 2002 |
|
Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole. | 2002 |
|
Lack of clinically relevant interaction between desloratadine and erythromycin. | 2002 |
|
Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. | 2002 |
|
A pharmacokinetic profile of desloratadine in healthy adults, including elderly. | 2002 |
|
Treatment of allergic rhinitis. | 2002 Dec 16 |
|
[The result of neglected or erroneous treatment. Mentally handicapped by hay fever]. | 2002 Jul 11 |
|
Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. | 2002 Nov |
|
Clinical pharmacology of H1-antihistamines in the skin. | 2002 Nov |
|
Desloratidine for the treatment of chronic urticaria. | 2002 Oct |
|
Desloratadine reduces allergen challenge-induced mucinous secretion and plasma exudation in allergic rhinitis. | 2002 Oct |
|
Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. | 2002 Oct |
|
Efficacy of once-daily desloratadine/pseudoephedrine for relief of nasal congestion. | 2002 Sep-Oct |
|
Severe hepatotoxicity after application of desloratadine and fluconazole. | 2003 |
|
Desloratadine: an update of its efficacy in the management of allergic disorders. | 2003 |
|
Chronic urticaria: a role for newer immunomodulatory drugs? | 2003 |
|
Pharmacokinetic properties of single-dose loratadine and ambroxol alone and combined in tablet formulations in healthy men. | 2003 Aug |
|
Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine. | 2003 Aug |
|
Studies on performance and sleepiness with the H1-antihistamine, desloratadine. | 2003 Aug |
|
Gateways to clinical trials. | 2003 Dec |
|
Comparative in vivo bioactivity of modern H1-antihistamines on AMP challenge in atopic asthma. | 2003 Feb |
|
The effect of ketotifen on inflammatory markers in allergic conjunctivitis: an open, uncontrolled study. | 2003 Jan 6 |
|
Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial. | 2003 Jul |
|
Pharmacokinetics of loratadine and its active metabolite descarboethoxyloratadine in healthy Chinese subjects. | 2003 Jul |
|
Desloratadine inhibits allergen-induced airway inflammation and bronchial hyperresponsiveness and alters T-cell responses in murine models of asthma. | 2003 Jul |
|
Validation of a sensitive and automated 96-well solid-phase extraction liquid chromatography-tandem mass spectrometry method for the determination of desloratadine and 3-hydroxydesloratadine in human plasma. | 2003 Jul 25 |
|
[Safety of new antihistamines]. | 2003 Jun |
|
[Clinical aspects of anti-inflammatory action of antihistamines]. | 2003 Jun |
|
The effects of histamine and leukotriene receptor antagonism on nasal mannitol challenge in allergic rhinitis. | 2003 Jun |
|
Comparison of the effects of desloratadine 5-mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure. | 2003 Jun |
|
Gateways to clinical trials. March 2003. | 2003 Mar |
|
Double-stranded RNA viruses in a mycocinogenic strain of Cystofilobasidium infirmominiatum. | 2003 Mar |
|
Decongestant effects of antihistamines: a class effect? | 2003 Mar |
|
Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. | 2003 Mar |
|
First do no harm: managing antihistamine impairment in patients with allergic rhinitis. | 2003 May |
|
[Multicenter study of the effectiveness and tolerability of desloratadine in seasonal allergic rhinitis]. | 2003 May 25 |
|
Loratadine, desloratadine and pregnancy: don't use, risk of hypospadias. | 2003 Oct |
|
A comparison of the effect of diphenhydramine and desloratadine on vigilance and cognitive function during treatment of ragweed-induced allergic rhinitis. | 2003 Oct |
|
Efficacy and safety profile of fexofenadine HCl: a unique therapeutic option in H1-receptor antagonist treatment. | 2003 Oct |
|
Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin. | 2003 Oct |
|
Twenty-four-hour activity and consistency of activity of levocetirizine and desloratadine in the skin. | 2003 Oct |
|
Improvements in simulated real-world relevant performance for patients with seasonal allergic rhinitis: impact of desloratadine. | 2004 Apr |
|
Inhibition of cold urticaria by desloratadine. | 2004 Jan |
|
Anti-inflammatory activity of H1-receptor antagonists: review of recent experimental research. | 2004 Jan |
|
Gateways to clinical trials. | 2004 Jan-Feb |
|
High-performance liquid chromatographic method for the bioequivalence evaluation of desloratadine fumarate tablets in dogs. | 2004 Mar 10 |
Patents
Sample Use Guides
Adults and Adolescents 12 Years of Age and Over:
take 5 mg tablet once daily. Children 6 to Years of Age: take 2.5 mg tablet once daily. Children 12 Months to 5 Years of Age: take 1.25 mg tablet once daily. Children 6 to 11 Months of Age: 1 mg tablet once daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7677235
Nasal epithelial cells (activated by 1 uM of histamine) were treated with 10 uM of desloratadine and the inhibitory activity of the drug on expression of ICAM-1 and HLA-DR was studied.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sun Dec 18 17:37:55 UTC 2022
by
admin
on
Sun Dec 18 17:37:55 UTC 2022
|
Record UNII |
FVF865388R
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EMA ASSESSMENT REPORTS |
DESLORATADINE TEVA (AUTHORIZED: RHINITIS, ALLERGIC, SEASONAL)
Created by
admin on Sun Dec 18 17:38:01 UTC 2022 , Edited by admin on Sun Dec 18 17:38:01 UTC 2022
|
||
|
LIVERTOX |
NBK548831
Created by
admin on Sun Dec 18 17:38:01 UTC 2022 , Edited by admin on Sun Dec 18 17:38:01 UTC 2022
|
||
|
WHO-VATC |
QR06AX27
Created by
admin on Sun Dec 18 17:38:01 UTC 2022 , Edited by admin on Sun Dec 18 17:38:01 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
OPULIS (WITHDRAWN: RHINITIS, URTICARIA)
Created by
admin on Sun Dec 18 17:38:01 UTC 2022 , Edited by admin on Sun Dec 18 17:38:01 UTC 2022
|
||
|
NCI_THESAURUS |
C29578
Created by
admin on Sun Dec 18 17:38:01 UTC 2022 , Edited by admin on Sun Dec 18 17:38:01 UTC 2022
|
||
|
NDF-RT |
N0000175587
Created by
admin on Sun Dec 18 17:38:01 UTC 2022 , Edited by admin on Sun Dec 18 17:38:01 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
ALLEX(WITHDRAWN: RHINITIS, ALLERGIC, SEASONAL)
Created by
admin on Sun Dec 18 17:38:01 UTC 2022 , Edited by admin on Sun Dec 18 17:38:01 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
DASSELTA (AUTHORIZED: RHINITIS, ALLERGIC, SEASONAL)
Created by
admin on Sun Dec 18 17:38:01 UTC 2022 , Edited by admin on Sun Dec 18 17:38:01 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
DESLORATADINE RATIOPHARM (AUTHORIZED: RHINITIS, ALLERGIC, SEASONAL)
Created by
admin on Sun Dec 18 17:38:01 UTC 2022 , Edited by admin on Sun Dec 18 17:38:01 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
DESLORATADINE ACTAVIS (AUTHORIZED: RHINITIS, URTICARIA)
Created by
admin on Sun Dec 18 17:38:01 UTC 2022 , Edited by admin on Sun Dec 18 17:38:01 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
AZOMYR (AUTHORIZED: RHINITIS, ALLERGIC, SEASONAL)
Created by
admin on Sun Dec 18 17:38:01 UTC 2022 , Edited by admin on Sun Dec 18 17:38:01 UTC 2022
|
||
|
WHO-ATC |
R06AX27
Created by
admin on Sun Dec 18 17:38:01 UTC 2022 , Edited by admin on Sun Dec 18 17:38:01 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
AERINAZE (AUTHORIZED: RHINITIS)
Created by
admin on Sun Dec 18 17:38:01 UTC 2022 , Edited by admin on Sun Dec 18 17:38:01 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
AERIUS(AUTHORIZED: RHINITIS, ALLERGIC, SEASONAL)
Created by
admin on Sun Dec 18 17:38:01 UTC 2022 , Edited by admin on Sun Dec 18 17:38:01 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
NEOCLARITYN (AUTHORIZED: RHINITIS, URTICARIA)
Created by
admin on Sun Dec 18 17:38:01 UTC 2022 , Edited by admin on Sun Dec 18 17:38:01 UTC 2022
|
||
|
NDF-RT |
N0000000190
Created by
admin on Sun Dec 18 17:38:01 UTC 2022 , Edited by admin on Sun Dec 18 17:38:01 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL1172
Created by
admin on Sun Dec 18 17:38:01 UTC 2022 , Edited by admin on Sun Dec 18 17:38:01 UTC 2022
|
PRIMARY | |||
|
DB00967
Created by
admin on Sun Dec 18 17:38:01 UTC 2022 , Edited by admin on Sun Dec 18 17:38:01 UTC 2022
|
PRIMARY | |||
|
1370280
Created by
admin on Sun Dec 18 17:38:01 UTC 2022 , Edited by admin on Sun Dec 18 17:38:01 UTC 2022
|
ALTERNATIVE | |||
|
C121345
Created by
admin on Sun Dec 18 17:38:01 UTC 2022 , Edited by admin on Sun Dec 18 17:38:01 UTC 2022
|
PRIMARY | |||
|
291342
Created by
admin on Sun Dec 18 17:38:01 UTC 2022 , Edited by admin on Sun Dec 18 17:38:01 UTC 2022
|
PRIMARY | |||
|
7817
Created by
admin on Sun Dec 18 17:38:01 UTC 2022 , Edited by admin on Sun Dec 18 17:38:01 UTC 2022
|
PRIMARY | |||
|
275635
Created by
admin on Sun Dec 18 17:38:01 UTC 2022 , Edited by admin on Sun Dec 18 17:38:01 UTC 2022
|
PRIMARY | RxNorm | ||
|
DTXSID1044196
Created by
admin on Sun Dec 18 17:38:01 UTC 2022 , Edited by admin on Sun Dec 18 17:38:01 UTC 2022
|
PRIMARY | |||
|
Desloratadine
Created by
admin on Sun Dec 18 17:38:01 UTC 2022 , Edited by admin on Sun Dec 18 17:38:01 UTC 2022
|
PRIMARY | |||
|
C47474
Created by
admin on Sun Dec 18 17:38:01 UTC 2022 , Edited by admin on Sun Dec 18 17:38:01 UTC 2022
|
PRIMARY | |||
|
759824
Created by
admin on Sun Dec 18 17:38:01 UTC 2022 , Edited by admin on Sun Dec 18 17:38:01 UTC 2022
|
PRIMARY | |||
|
124087
Created by
admin on Sun Dec 18 17:38:01 UTC 2022 , Edited by admin on Sun Dec 18 17:38:01 UTC 2022
|
PRIMARY | |||
|
KK-46
Created by
admin on Sun Dec 18 17:38:01 UTC 2022 , Edited by admin on Sun Dec 18 17:38:01 UTC 2022
|
PRIMARY | |||
|
814
Created by
admin on Sun Dec 18 17:38:01 UTC 2022 , Edited by admin on Sun Dec 18 17:38:01 UTC 2022
|
PRIMARY | |||
|
FVF865388R
Created by
admin on Sun Dec 18 17:38:01 UTC 2022 , Edited by admin on Sun Dec 18 17:38:01 UTC 2022
|
PRIMARY | |||
|
FVF865388R
Created by
admin on Sun Dec 18 17:38:01 UTC 2022 , Edited by admin on Sun Dec 18 17:38:01 UTC 2022
|
PRIMARY | |||
|
Desloratadine
Created by
admin on Sun Dec 18 17:38:01 UTC 2022 , Edited by admin on Sun Dec 18 17:38:01 UTC 2022
|
PRIMARY | |||
|
1173042
Created by
admin on Sun Dec 18 17:38:01 UTC 2022 , Edited by admin on Sun Dec 18 17:38:01 UTC 2022
|
PRIMARY | |||
|
7157
Created by
admin on Sun Dec 18 17:38:01 UTC 2022 , Edited by admin on Sun Dec 18 17:38:01 UTC 2022
|
PRIMARY | |||
|
M4193
Created by
admin on Sun Dec 18 17:38:01 UTC 2022 , Edited by admin on Sun Dec 18 17:38:01 UTC 2022
|
PRIMARY | Merck Index | ||
|
SUB01596MIG
Created by
admin on Sun Dec 18 17:38:01 UTC 2022 , Edited by admin on Sun Dec 18 17:38:01 UTC 2022
|
PRIMARY | |||
|
100643-71-8
Created by
admin on Sun Dec 18 17:38:01 UTC 2022 , Edited by admin on Sun Dec 18 17:38:01 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
TRANSPORTER -> INHIBITOR |
Ki
|
||
|
METABOLIC ENZYME -> NON-INHIBITOR | |||
|
METABOLIC ENZYME -> NON-INHIBITOR | |||
|
BINDER->LIGAND |
BINDING
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
METABOLIC ENZYME -> NON-INHIBITOR | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> INHIBITOR |
WEAK
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
TRANSPORTER -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT | |||
|
METABOLIC ENZYME -> INHIBITOR |
WEAK
|
||
|
TARGET -> INHIBITOR |
Kd
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> INHIBITOR |
WEAK
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> NON-INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
||
|
PARENT -> METABOLITE ACTIVE |
MAJOR
|
||
|
METABOLITE -> PARENT |
IN VITRO
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Tmax | PHARMACOKINETIC |
|
DOSE |
|
||
Biological Half-life | PHARMACOKINETIC |
|
|
|||